title: CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children.
abstract: Despite the availability of measles vaccines, infants continue to die from measles. Measles vaccine responses vary between individuals, and poor immunogenicity is likely to preclude protection against measles. CD46 is a ubiquitously expressed specific receptor for vaccine strains of measles virus. CD46 polymorphisms have not been functionally investigated but may affect CD46 protein expression, which in turn may mediate primary measles antibody responses in infants. In a cohort of children aged 12 to 14 months from Perth, Australia (n = 137), after their first dose of measles-mumps-rubella (MMR) vaccine, CD46 polymorphisms were genotyped, and postvaccination measles IgG and CD46 protein expression before and after measles lysate stimulation of cells were measured. Three CD46 variants (rs7144, rs11118580, and rs2724384) were significantly associated with measles virus-specific IgG levels (P = 0.008, P = 0.026, and P = 0.018, respectively). There were significant differences between CD46 rs7144 genotypes and CD46 protein expression on T cells, as well as the downregulation of CD46 and T-cell frequency after measles lysate stimulation. We show that CD46 polymorphisms were associated with primary measles antibody responses in naive infants. We also report the first association of a measles virus receptor polymorphism with functional effects on the receptor, suggesting a possible mechanism through which antibody responses are altered. Elucidating all of the interconnecting genetic factors that alter primary measles vaccine responses may be important for identifying children at risk of poor immunogenicity or vaccine failure and for the future design of vaccine strategies to help these children.
authors.affiliation: School of Paediatrics and Child Health, University of Western Australia, Perth, Australia. holly.clifford@gmail.com
authors.forename: Holly D
authors.initials: HD
authors.lastname: Clifford
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Hayden
authors.forename: Siew-Kim
authors.initials: SK
authors.lastname: Khoo
authors.forename: Guicheng
authors.initials: G
authors.lastname: Zhang
authors.forename: Peter N
authors.initials: PN
authors.lastname: Le Souëf
authors.forename: Peter
authors.initials: P
authors.lastname: Richmond
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D001315:Australia; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008297:Male; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D051916:Membrane Cofactor Protein / Q000235:genetics*; D011110:Polymorphism, Genetic; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; C497857:CD46 protein, human; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine; D051916:Membrane Cofactor Protein